Cocrystal Targets Norovirus With Strain-Specific Drug

Cocrystal's CDI-988 oral antiviral is in a placebo-controlled challenge study at Emory University as Moderna's norovirus vaccine falls short of early success criteria.

Updated on Nov. 4, 2026 in COVID-19

Cocrystal Targets Norovirus With Strain-Specific Drug

Live Poll

Do you trust that new norovirus treatments will be developed in the coming years?

Cocrystal's CDI-988, an oral antiviral, is being tested in a placebo-controlled phase 1b human challenge study at Emory University School of Medicine, which has completed dosing its last participant. The effort comes after Moderna's norovirus vaccine candidate mRNA-1403 did not meet statistical criteria for early success at phase 3 interim analysis.

Why it matters

Norovirus causes an estimated 685 million illnesses worldwide and no specific medication currently treats it, leaving a significant gap in treatment options. Cocrystal is pursuing a narrower approach than earlier efforts that targeted the full range of strains.

The CDC estimates norovirus causes roughly 900 deaths and 109,000 hospitalizations annually in the U.S., while worldwide the virus is responsible for an estimated 685 million illnesses. Results from Cocrystal's challenge study remain unreported, with preliminary data expected in late 2026 or early 2027.

The players

Cocrystal Pharma

Cocrystal Pharma is a biopharmaceutical company developing antiviral drug candidates, including CDI-988 for norovirus.

Moderna

Moderna is a biotechnology company best known for its mRNA COVID-19 vaccine, which is also developing a norovirus vaccine candidate.

Emory University School of Medicine

Emory University School of Medicine is a major academic medical center in Atlanta, Georgia, hosting the CDI-988 human challenge study.

Centers for Disease Control and Prevention

The Centers for Disease Control and Prevention is the U.S. federal agency that publishes national estimates of norovirus illnesses, hospitalizations, and deaths.

The details

Cocrystal is testing CDI-988 in a placebo-controlled phase 1b challenge study at Emory University School of Medicine, focusing on one specific norovirus strain rather than the full range of strains. The company says it will pursue the other strains if the strain-specific approach proves effective.

July 2026: Moderna reported mRNA-1403 did not meet early success criteria at phase 3 interim analysis.
Late 2026 or early 2027: Cocrystal expects preliminary results from the CDI-988 study.

Health Landscape

Moderna's mRNA-1403 norovirus vaccine program, which failed to meet early success criteria at phase 3 interim analysis, leaves antiviral treatments like Cocrystal's CDI-988 as an alternative path. Because no specific norovirus medication exists today, the outcome of both approaches will shape how the disease is managed in the coming years.

Norovirus currently has no specific treatment, so people with severe illness rely on supportive care such as hydration. If CDI-988 succeeds, it could give patients and clinicians an oral option for treating or preventing infection.

The takeaway

Norovirus remains a major source of illness and cost with no approved drug, so readers should watch for preliminary results from clinical studies before expecting new treatment options. Hygiene measures such as frequent handwashing and thorough cleaning remain the main protection in the meantime.

What happens next

Cocrystal expects preliminary results from the CDI-988 challenge study in late 2026 or early 2027, and says it will pursue additional norovirus strains if the strain-specific approach succeeds.